Solifenacin

Generic Name
Solifenacin
Brand Names
Vesicare
Drug Type
Small Molecule
Chemical Formula
C23H26N2O2
CAS Number
242478-37-1
Unique Ingredient Identifier
A8910SQJ1U
Background

Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.

Solifenacin was granted FDA approval on 19 November 2004.

Indication

Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

Associated Conditions
Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
Associated Therapies
-
Clinical Trials
Related News

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

First Posted Date
2008-10-16
Last Posted Date
2016-12-06
Lead Sponsor
Stamford Hospital
Registration Number
NCT00773552
Locations
🇺🇸

The Stamford Hospital, Stamford, Connecticut, United States

🇺🇸

Optimus Health care, Stamford, Connecticut, United States

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

First Posted Date
2008-10-13
Last Posted Date
2013-02-15
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
638
Registration Number
NCT00771394

Feasibility of "At-home" Titration of Solifenacin

Phase 4
Terminated
Conditions
Overactive Bladder
Interventions
Drug: Solifenacin
First Posted Date
2008-09-25
Last Posted Date
2015-10-26
Lead Sponsor
NYU Langone Health
Target Recruit Count
36
Registration Number
NCT00759577

A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder

First Posted Date
2008-06-17
Last Posted Date
2016-01-07
Lead Sponsor
KYU-SUNG LEE
Target Recruit Count
94
Registration Number
NCT00699049

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

First Posted Date
2008-03-06
Last Posted Date
2024-11-14
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
249
Registration Number
NCT00629642

Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy

Not Applicable
Terminated
Conditions
Incontinence
Interventions
Drug: Vesicare
First Posted Date
2007-12-27
Last Posted Date
2010-10-07
Lead Sponsor
University of California, Irvine
Target Recruit Count
13
Registration Number
NCT00581061
Locations
🇺🇸

University of California, Irvine Medical Center, Orange, California, United States

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

First Posted Date
2007-12-14
Last Posted Date
2010-10-05
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
768
Registration Number
NCT00573508

A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH

First Posted Date
2007-08-02
Last Posted Date
2014-08-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
919
Registration Number
NCT00510406

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

First Posted Date
2007-07-26
Last Posted Date
2014-08-06
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
222
Registration Number
NCT00507455

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

Phase 3
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: solifenacin succinate
First Posted Date
2007-04-20
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
2225
Registration Number
NCT00463541
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy